Latest & greatest articles for venlafaxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on venlafaxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on venlafaxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for venlafaxine

21. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder (Full text)

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder The Prevention of Recurrent Episodes of Depression with venlafaxine XR for Two Years trial has reported advantages with maintenance treatment for patients with recurrent depressive disorder. The aim of this study was to assess the cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder, based on a recent clinical trial.A Markov (...) simulation model was constructed to assess the cost-utility of maintenance treatment for 2 years in recurrently depressed patients in Sweden. Risk of relapse and recurrence was based on a recent randomised clinical trial assessing the efficacy and tolerability of maintenance treatment with venlafaxine over 2 years. Costs and quality of life estimations were retrieved from a naturalistic longitudinal observational study conducted in Sweden. Health effects were quantified as quality-adjusted life-years

2008 EvidenceUpdates PubMed

22. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder

Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Article Text Therapeutics Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Mental Health

23. Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs (Full text)

Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs Higher dose venlafaxine may improve response compared with standard doses in people with major depressive disorder and intolerance or non-responsiveness to SSRIs | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher dose venlafaxine may improve response compared

2008 Evidence-Based Mental Health PubMed

24. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. (Full text)

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. Only about 60% of adolescents with depression will show an adequate clinical response to an initial treatment trial with a selective serotonin reuptake inhibitor (SSRI). There are no data to guide clinicians on subsequent treatment strategy.To evaluate the relative efficacy of 4 treatment strategies in adolescents who (...) behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cognitive behavioral therapy.Clinical Global Impressions-Improvement score of 2 or less (much or very much improved) and a decrease of at least 50% in the Children's Depression Rating Scale-Revised (CDRS-R); and change in CDRS-R over time.Cognitive behavioral therapy plus a switch to either medication regimen showed a higher response rate (54.8%; 95% confidence interval [CI], 47%-62%) than a medication switch

2008 JAMA PubMed

25. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

2008 NHS Economic Evaluation Database.

26. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. (Full text)

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Major depressive disorder (MDD), a prevalent and serious mental illness, is associated with a substantial disease and economic burden. Long-term pharmacotherapy is often necessary; selective serotonin reuptake inhibitors (SSRIs) or the serotonin-noradrenaline reuptake inhibitor venlafaxine are the most frequently prescribed medications (...) in patients with moderate-to-severe depressive symptoms. This article reviews head-to-head clinical studies and health economic models comparing the efficacy, tolerability and cost-effectiveness of escitalopram, a dual-action selective inhibitor of serotonin reuptake, and the extended-release (XR) formulation of venlafaxine. While there has been some evidence that conventional SSRIs are inferior to venlafaxine in terms of efficacy, escitalopram was at least as effective as venlafaxine XR in reducing

2007 EvidenceUpdates PubMed

27. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. (Full text)

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin.Retrospective cohort study.UK General Practice Research Database.219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005.Completed suicide and attempted suicide.Venlafaxine users had (...) a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared with dothiepin were 2.54 (1.07

2007 BMJ PubMed

28. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary (...) care Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in the primary

2007 NHS Economic Evaluation Database.

29. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. (PubMed)

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 (...) weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory

2006 NEJM

30. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment

2006 Evidence-Based Mental Health

31. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents (Full text)

Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Article Text Therapeutics Venlafaxine offers no benefit over sertraline

2005 Evidence-Based Mental Health PubMed

32. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom Guest J F, Russ J, Lenox-Smith A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the effectiveness and costs of venlafaxine XL (Efexor XL) and diazepam for the treatment of generalised anxiety disorder (GAD) among non-depressed patients. Patients received either 75 mg venlafaxine XL once daily or 5 mg diazepam 3

2005 NHS Economic Evaluation Database.

33. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK Wade A G, Toumi (...) daily) and venlafaxine-XR (VEN; 75 - 150 mg daily). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of adult patients (older than 18 years) with MDD. MDD was defined as baseline scores in the range of 18 to 40 inclusive on the Montgomery-Asberg Depression Rating Scale (MADRS). Setting The setting was primary care. The economic study was carried out in the UK. Dates to which data relate

2005 NHS Economic Evaluation Database.

34. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Fernandez J L, Montgomery S, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of escitalopram, a selective serotonin reuptake inhibitor, in the treatment of major depressive disorder (MMD). The comparator was venlafaxine RX, a serotonin noradrenaline (norepinephrine) reuptake inhibitor with established efficacy in MMD. Type of intervention Treatment. Economic study type Cost-utility analysis

2005 NHS Economic Evaluation Database.

35. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium Demyttenaere K, Hemels M E, Hudry J, Annemans L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies compared were escitalopram (10 - 20 mg/day), citalopram (20 - 40 mg/day) and venlafaxine (75 - 150 mg/day) as first-line treatment for major depressive disorder (MDD). MDD was defined as baseline

2005 NHS Economic Evaluation Database.

36. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major (...) depressive disorder Trivedi M H, Wan G J, Mallick R, Chen J L, Casciano R, Geissler E C, Panish J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine extended release (VXR) was compared with selective serotonin reuptake

2004 NHS Economic Evaluation Database.

37. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Smith D, Dempster C, Glanville J, Freemantle N, Anderson I Authors' objectives (...) To investigate the relative efficacy and tolerability of venlafaxine compared with other antidepressants. Searching Relevant trials were identified from the authors' existing database (see Other Publications of Related interest no.1). In addition, the following databases were searched: MEDLINE, EMBASE, BIOSIS Previews, PsycLIT, the National Research Register, HealthSTAR, SIGLE, the Cochrane Controlled Trials Register and the Current Controlled Trials Register. The keywords were 'venlafaxine', 'efexor

2002 DARE.

38. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. (PubMed)

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear (...) of breast cancer.Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity

2000 Lancet

39. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. (PubMed)

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Generalized anxiety disorder (GAD) is a chronic disorder that is associated with debilitating psychic and somatic symptoms. Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent (...) confers persistent benefits.To compare the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in outpatients with GAD without associated MDD.Six-month, randomized, double-blind, placebo-controlled, parallel-group trial conducted May 1996 to October 1997.Fourteen outpatient clinics and private psychiatric practices in the United States.A total of 251 outpatients aged 18 years or older who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for GAD

2000 JAMA

40. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Einarson T R, Addis A, Iskedjian M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine in the treatment of acute depressive disorders. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patient characteristics are published elsewhere, with a meta-analysis of effectiveness data. Setting Inpatient and outpatient settings were included. The economic analysis was carried out in Ontario, Canada. Dates to which data

1997 NHS Economic Evaluation Database.